Health Condition 1: G258- Other specified extrapyramidal andmovement disorders
Conditions
Interventions
Intervention1: Tab Levodopa 125 mg TDS: Tablet Levodopa 125 mg will be started and will be hiked to the desired dose of 125 mg TDS in 10 day.
Control Intervention1: Nil: Nil
Sponsors
AIIMS New delhi
Eligibility
Inclusion criteria
Inclusion criteria: •All adult patients with genetically proven diagnosis of SCA 12 •Presence of clinical features of parkinsonism, as assessed and agreed upon by two movement disorder experts, according to the UK Brain Bank criteria for diagnosis of parkinsonism •Patients on a stable dose of symptomatic medication (e.g. beta-blockers for tremor) for three months prior to enrolment
Exclusion criteria
Exclusion criteria: Participants meeting any one of the following will be excluded . 1.Patients with history of use of any antipsychotic medications, or drugs that can cause drug-induced parkinsonism like D2-blockers etc. in the past 2.Pregnant and lactating females 3.Chronic diseases like Chronic Kidney Disease, Chronic Liver Disease 4.Known allergies or intolerance to levodopa therapy 5.Patients already on levodopa therapy at the time of recruitment 6.Patients who are unwilling to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in MDS UPDRS part III score from baseline at three months of levodopa therapy among patients with genetically proven Spino cerebellar ataxia 12 with clinical parkinsonism.Timepoint: baseline and at three months | — |
Secondary
| Measure | Time frame |
|---|---|
| Striatal outcomes using DAT scan in persons with SCA 12Timepoint: at baseline;To assess improvement from baseline in Quality of life using SF 36 , Tremors(tetras score), Non motor symptoms scoreTimepoint: at baseline and 3 months;Correlation between CAG trinucleotide repeats and Levodopa responseTimepoint: at baseline and at 3 months | — |
Countries
India
Contacts
Public ContactDr Lekshmi S H
AIIMS New delhi
Outcome results
None listed